Guttman-Yassky, E., Blauvelt, A., Eichenfield, L., Paller, A., Armstrong, A., Drew, J., Gopalan, R. and Simpson, E. 2019. Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S41. DOI:https://doi.org/10.25251/skin.3.supp.41.